Streamex  to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th

Streamex to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th

BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ: BSGM), a gold tokenization infrastructure company building the foundation for on-chain gold markets, today announced that it will participate in the 5 th annual Needham Virtual Crypto 1x1 Conference on September 4 th 2025. BioSig and Streamex CEO, Henry McPhie and CIO, Mitch Williams will host one on one meetings with institutional investors at the conference.

About Streamex

Streamex is an RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market on chain, enabled by a gold denominated treasury and tokenization technology powering the gold market of tomorrow.  Streamex is a wholly owned subsidiary of BioSig Technologies, Inc.

About BioSig Technolgies

BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EPâ„¢ Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.


Contacts BioSig/Streamex Press & Investor Relations: Adele Carey Alliance Advisors Investor Relations acarey@allianceadvisors.com Henry McPhie CEO of BioSig, Co-Founder of Streamex IR@Biosigtech.com contact@Streamex.com https://www.streamex.com/ https://x.com/streamex

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

BSGM
BioSig Technologies

BioSig Technologies Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BioSig Technologies

BioSig Technologies

Overview

BioSig Technologies (OTCQB:BSGM) is a medical device company that has developed a proprietary technology platform targeting the rapidly growing electrophysiology (EP) device market. EP devices are used in the treatment of cardiac arrhythmias, which can lead to stroke or even death. The current standard of care is cardiac catheter ablation which has a low efficacy rate.

BioSig Technologies’ goal is to bring to market an advanced biomedical signal processing technology that can address unmet needs for the treatments of challenging and chronic diseases such as arrhythmias. The company is advancing towards commercialization of its PURE EPTM System which is designed to improve the clarity of clinical signals available for EP studies and ablation procedures.

Bringing Next Gen EP Device to Market

Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals

Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals

Partnership unlocks exclusive tokenization rights, a four percent (4%) annual yield target on physical bullion, revenue share tied to leasing volumes and the creation of a groundbreaking institutionalized asset providing yield on physical gold holdings

Key Partnership Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ: BSGM), today provided an update regarding the status of the merger and related proxy materials.

The merger transaction closed on May 28, 2025, under the previously executed Share Purchase Agreement. As part of this transaction, 19.99% of BioSig shares are already issuable to Streamex shareholders, with the remaining issuances pending Nasdaq approval.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

BioSig Technologies, Inc. (NASDAQ: BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer. Personal Bio, Ferdinand Groenewald, age 39 Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at Financial Consulting Strategies LLC; a Controller, VP-Finance & Accounting Officer at Sadot Group, Inc. and a Chief Financial Officer at the same company; and Chief Accounting Officer & VP-Finance at Muscle Maker Development LLC. Mr. Groenewald obtained an undergraduate degree from the University of South Africa.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company") a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share and concurrent private placement unregistered warrants to purchase up to 1,570,683 shares of common stock at an exercise price of $1.78 per share. The unregistered warrants are immediately exercisable and will expire five years from the date of issuance.

H.C. Wainwright & Co. acted as exclusive placement agent for the offering.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company") a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, BioSig has also agreed to issue and sell to the same purchasers unregistered warrants to purchase up to 1,570,683 shares of common stock at an exercise price of $1.78 per share. The unregistered warrants will become immediately exercisable upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about May 30, 2024, subject to the satisfaction of customary closing conditions.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioSig Technologies

BioSig Technologies Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×